Filtros de búsqueda

Lista de obras de

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 ⬇️

artículo científico publicado el 1 de octubre de 2010

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

artículo científico publicado en 2016

A functional landscape of resistance to ALK inhibition in lung cancer

artículo científico publicado en 2015

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

artículo científico publicado en 2012

A new device for rapid isolation by size and characterization of rare circulating tumor cells

artículo científico publicado en 2011

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

artículo científico publicado en 2011

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

artículo científico publicado en 2010

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib

artículo científico publicado en 2014

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

artículo científico publicado en 2009

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

artículo científico publicado en 2015

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

artículo científico publicado en 2017

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer

artículo científico publicado en 2012

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

artículo científico publicado en 2006

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples

artículo científico publicado en 2006

A severe photosensitivity dermatitis caused by crizotinib

artículo científico publicado en 2014

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

artículo científico publicado en 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

artículo científico publicado en 2015

Abstract 1196: Characterization of ALK splicing isoforms in EML4-ALK-translocated lung cancer

artículo científico publicado en 2013

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

artículo científico publicado en 2015

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

artículo científico publicado en 2016

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

artículo científico publicado en 2013

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

artículo científico publicado en 2012

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 12 de octubre de 2010

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development

artículo científico publicado en 2016

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification

artículo científico publicado en 2009

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers

artículo científico publicado en 2011

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

artículo científico publicado en 2012

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays

artículo científico publicado en 2004

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

artículo científico publicado en 2010

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

artículo científico publicado en 2008

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers

artículo científico publicado en 2008

Basic treatment considerations using chemotherapy for patients with small cell lung cancer

artículo científico publicado en 2004

Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

artículo científico publicado en 2015

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

artículo científico publicado en 2015

Biotinylated Probe Isolation of Targeted Gene Region Improves Detection of T790M Epidermal Growth Factor Receptor Mutation via Peptide Nucleic Acid–Enriched Real-Time PCR ⬇️

artículo científico publicado el 16 de febrero de 2011

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

artículo científico publicado en 2007

Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment

artículo científico publicado en 2005

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool

artículo científico publicado en 2010

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

artículo científico publicado en 2008

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

artículo científico publicado en 2013

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial ⬇️

artículo científico publicado el 1 de septiembre de 2010

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors

artículo científico publicado en 2014

Circumventing cancer drug resistance in the era of personalized medicine

artículo científico publicado en 2012

Clinical Implications of Variant ALK FISH Rearrangement Patterns

artículo científico publicado en 2015

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine

artículo científico publicado en 2016

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine

article

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology

artículo científico publicado en 2011

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

artículo científico publicado en 2009

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer

artículo científico publicado en 2013

Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR.

artículo científico publicado en 2009

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

artículo científico publicado en 2015

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

artículo científico publicado en 2012

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study

artículo científico publicado en 2016

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

artículo científico publicado en 2009

Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer.

artículo científico publicado en 2002

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

artículo científico publicado en 2017

Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target

artículo científico publicado en 2012

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors

artículo científico publicado en 2016

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

artículo científico publicado en 2014

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

artículo científico publicado en 2015

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

artículo científico publicado en 2015

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

artículo científico publicado en 2014

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

artículo científico publicado en 2005

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

artículo científico publicado en 2009

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

artículo científico publicado en 2011

Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation

artículo científico publicado en 2015

Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor

scholarly article by Jaebong Jang et al published 3 September 2018 in Angewandte Chemie International Edition

Discovery of a potent dual ALK and EGFR T790M inhibitor

artículo científico publicado en 2017

Discovery of selective irreversible inhibitors for EGFR-T790M.

artículo científico publicado en 2010

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.

artículo científico publicado en 2016

Drug discovery: inhibitors that activate

artículo científico publicado en 2010

EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib

artículo científico publicado en 2017

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

artículo científico publicado en 2017

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

artículo científico publicado en 2015

EGFR T790M mutation testing within the osimertinib AURA Phase I study

artículo científico publicado en 2017

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

artículo científico publicado en 2011

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

artículo científico publicado en 2005

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

artículo científico publicado en 2010

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

artículo científico publicado en 2009

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

artículo científico publicado en 2004

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

artículo científico publicado en 2011

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

artículo científico publicado en 2008

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

artículo científico publicado en 2006

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

artículo científico publicado en 2009

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

artículo científico publicado en 2008

Enhanced ratio of signals enables digital mutation scanning for rare allele detection

artículo científico publicado en 2015

Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone

artículo científico publicado en 2015

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

artículo científico

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

artículo científico publicado en 2006

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

artículo científico publicado en 2005

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer

artículo científico publicado en 2005

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

artículo científico publicado en 2005

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer

artículo científico publicado en 2017

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

artículo científico publicado en 2005

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

artículo científico publicado en 2008

Everolimus in Anaplastic Thyroid Cancer: A Case Series

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

artículo científico publicado en 2006

Factors predicting response to EGFR tyrosine kinase inhibitors

artículo científico publicado en 2005

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

artículo científico publicado en 2009

False positive plasma genotyping due to clonal hematopoiesis.

artículo científico publicado en 2018

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma

artículo científico publicado en 2006

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

artículo científico publicado en 2017

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

artículo científico publicado en 2008

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

artículo científico publicado en 2015

Fulminant hepatic failure secondary to erlotinib.

artículo científico publicado en 2007

Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?

artículo científico publicado en 2008

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

artículo científico publicado en 2004

Gefitinib therapy in non-small-cell lung cancer

artículo científico publicado en 2005

Gemcitabine-induced radiation recall

artículo científico publicado en 2002

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

artículo científico publicado en 2016

Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

artículo científico publicado en 2018

High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation

artículo científico publicado en 2005

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines

artículo científico publicado en 2004

Histology... For want of anything better?

artículo científico publicado en 2009

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

artículo científico publicado en 2005

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

artículo científico publicado en 2016

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

artículo científico publicado en 2012

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma

artículo científico publicado en 2014

Imaging of Lung Cancer in the Era of Molecular Medicine ⬇️

artículo científico publicado el 28 de enero de 2011

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

artículo científico publicado en 2016

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

artículo científico publicado en 2009

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

artículo científico publicado en 2012

In Reply

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.

artículo científico publicado en 2003

Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy

article

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma

artículo científico publicado en 2002

Inhibition of the met receptor in mesothelioma

artículo científico publicado en 2005

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

artículo científico publicado en 2015

Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization

artículo científico publicado en 2018

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

artículo científico publicado en 2017

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma ⬇️

artículo científico publicado el 1 de enero de 2011

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

artículo científico publicado en 2015

Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers

artículo científico publicado en 2009

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

artículo científico publicado en 2016

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

artículo científico publicado en 2007

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer

artículo científico publicado en 2014

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

artículo científico publicado en 2012

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

artículo científico publicado en 2008

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer

artículo científico publicado en 2013

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

artículo científico publicado en 2017

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

artículo científico

Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers

artículo científico publicado en 2014

Monitoring cancer through the blood

artículo científico publicado en 2014

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

artículo científico publicado en 2012

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

artículo científico publicado en 2007

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

artículo científico publicado en 2011

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

artículo científico publicado en 2011

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

artículo científico publicado en 2005

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy

artículo científico publicado en 2010

New strategies for treatment of ALK-rearranged non-small cell lung cancers

artículo científico publicado en 2011

New targetable oncogenes in non-small-cell lung cancer

artículo científico publicado en 2013

No Target Left Behind: Improving Therapeutic Options for ERBB2-Mutant Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

artículo científico publicado en 2009

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

scientific article published on 15 January 2014

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

artículo científico publicado en 2009

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

artículo científico publicado en 2005

Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study

artículo científico publicado en 2016

Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations

artículo científico publicado en 2005

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program

artículo científico publicado en 2005

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

artículo científico publicado en 2016

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

artículo científico publicado en 2017

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

artículo científico publicado en 2004

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery

artículo científico publicado en 2009

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

artículo científico publicado en 2007

Patterns of failure following surgical resection for malignant pleural mesothelioma

artículo científico publicado en 2004

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial

artículo científico publicado en 2008

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

artículo científico publicado en 2011

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

artículo científico publicado en 2014

Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors

artículo científico publicado en 2013

Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma

artículo científico publicado en 2006

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

artículo científico publicado en 2017

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

artículo científico publicado en 2015

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

artículo científico publicado en 2006

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

artículo científico publicado en 2008

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

artículo científico publicado en 2018

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2017

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

artículo científico publicado en 2017

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

artículo científico publicado en 2013

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes

artículo científico publicado en 2013

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

artículo científico publicado en 2016

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

artículo científico publicado en 2010

Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape

artículo científico

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations

artículo científico publicado en 2015

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis

artículo científico publicado en 2016

Progress on Covalent Inhibition of KRAS(G12C).

artículo científico publicado en 2016

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial

artículo científico publicado en 2016

Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer.

artículo científico publicado en 2003

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

artículo científico publicado en 2013

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas

artículo científico publicado en 2013

ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.

artículo científico publicado en 2012

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

artículo científico publicado en 2012

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways

artículo científico publicado en 2011

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

artículo científico publicado en 2011

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

artículo científico publicado en 2012

Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer

artículo científico publicado en 2014

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

artículo científico publicado en 2014

Ras pathway activation in malignant mesothelioma

artículo científico publicado en 2007

Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer

artículo científico publicado en 2007

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer

artículo científico publicado en 2006

Resistance in trans-ition

artículo científico publicado en 2017

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

artículo científico publicado en 2009

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

artículo científico publicado en 2012

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

artículo científico publicado en 2017

Response and acquired resistance to everolimus in anaplastic thyroid cancer

artículo científico publicado en 2014

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

artículo científico publicado en 2006

Responsiveness to cetuximab without mutations in EGFR.

artículo científico publicado en 2005

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer ⬇️

artículo científico publicado el 17 de marzo de 2011

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

artículo científico publicado en 2018

Scientific Advances in Lung Cancer 2015.

artículo científico publicado en 2016

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

artículo científico publicado en 2005

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

artículo científico publicado en 2017

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

artículo científico publicado en 2013

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

artículo científico publicado en 2009

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

artículo científico publicado en 2008

Small Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver

artículo científico publicado en 2018

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.

artículo científico publicado en 2006

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation

artículo científico publicado en 2010

TGFβ pathway inhibition in the treatment of non-small cell lung cancer

artículo científico publicado en 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

artículo científico publicado en 2017

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers ⬇️

artículo científico publicado el 28 de octubre de 2010

The biology and treatment of EML4-ALK non-small cell lung cancer

artículo científico publicado en 2010

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board

artículo científico publicado en 2016

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

artículo científico publicado en 2006

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine

artículo científico publicado en 2016

The introduction of systematic genomic testing for patients with non-small-cell lung cancer

artículo científico publicado en 2012

The landscape of somatic copy-number alteration across human cancers

artículo científico publicado en 2010

The quest to overcome resistance to EGFR-targeted therapies in cancer

artículo científico publicado en 2013

The road to resistance: EGFR mutation and cetuximab.

artículo científico publicado en 2012

The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma

artículo científico publicado en 2003

Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma

artículo científico publicado en 2005

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor

artículo científico publicado en 2013

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

artículo científico publicado en 2014

Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives

artículo científico publicado en 2016

Translational medicine: Primed for resistance.

artículo científico publicado en 2012

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

artículo científico publicado en 2013

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

artículo científico publicado en 2002

Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex

artículo científico publicado en 2010

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

artículo científico publicado en 2009

Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer

artículo científico publicado en 2005

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer

artículo científico publicado en 2011

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression

artículo científico publicado en 2013

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

artículo científico publicado en 2014

Zeroing in on ROS1 rearrangements in non-small cell lung cancer.

artículo científico publicado en 2012

c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential

artículo científico publicado en 2012

s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis

artículo científico publicado en 2007

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda